Company Overview and News


Add BLUE
to your dashboard

Headline News

Cancer Space Update: Label Expansion for Three Major Drugs

7h zacks
With a busy earnings season almost coming to an end after an impressive run, we are again focused on latest cancer updates happening every week. The week gone by saw three cancer drugs receiving FDA approval for new indications – Roche Holding AG’s (RHHBY - Free Report) Gazyva, Pfizer Inc.’s (PFE - Free Report) Sutent and AstraZeneca PLC’s (AZN - Free Report) Faslodex. However, an interesting product in development is a cancer vaccine that Moderna Therapeutics and Merck (MRK - Free Report) are working on. (396-0)

$1 million price tag in spotlight as gene therapy becomes reality

2017-11-16 reuters
LONDON (Reuters) - Battle lines are being drawn as the first gene therapy for an inherited condition nears the U.S. market, offering hope for people with a rare form of blindness and creating a cost dilemma for healthcare providers. (14-1)

Your Daily Pharma Scoop: Progenics Looks Promising, Big Week For Dynavax, Keryx Ahead Of Catalyst

2017-11-06 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (692-3)

Small Cap ETFs in Focus as Domestic Growth Picks Momentum

2017-11-02 zacks
U.S. small-caps have been continuously lagging their large-cap counterparts this year. Large-cap stocks have been growing on stepped-up global economy, owing to their high international exposure. Small-cap stocks on the other hand are more domestically focused and exhibit higher volatility than their large-cap counterparts. (41-2)

ROTY Volume 1 Edition 45: More Trades And Updates

2017-11-02 seekingalpha
I finally cut a "loser" from the ROTY model account. While the fundamental thesis appears on track, I can`t ignore the weak technicals any longer. (68-1)

Your Daily Pharma Scoop: Teva Q3 Results, Boost For RedHill, Clovis Reports Rubraca Sales

2017-11-02 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Please click here or scroll down below to read an important announcement about changes and additions to the daily scoop. (685-3)

bluebird bio, Inc. 2017 Q3 - Results - Earnings Call Slides

2017-11-01 seekingalpha
The following slide deck was published by bluebird bio, Inc. in conjunction with their 2017 Q3 earnings call. (12-0)

With tweaks to gene therapy, Bluebird Bio makes progress in sickle cell

2017-11-01 statnews
t’s been two years since disappointing clinical trial results raised questions of whether Bluebird Bio (BLUE) was capable of developing a one-shot gene therapy cure for sickle cell disease. On Wednesday, the biotech disclosed the first preliminary data suggesting a significant obstacle may have been cleared. (12-0)

Your Daily Pharma Scoop: Portola's PDUFA, PDLI Makes Some Money, GWPH Completes Rolling NDA

2017-10-31 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Please click here or scroll down below to read an important announcement about changes and additions to the daily scoop. (765-3)

Why Earnings Season Could Be Great for bluebird bio (BLUE)

2017-10-30 zacks
Investors are always looking for stocks that are poised to beat at earnings season and bluebird bio, Inc. (BLUE - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report. (13-0)

Gilead Sciences, Inc. (GILD) Stock Isn’t Worth It Here

2017-10-29 investorplace
Gilead Sciences, Inc. (NASDAQ:GILD) has put together a nice run of late. The GILD stock price today sits 24% higher than it did as recently as June, when the stock hit a three-year low. (51-0)

Global Blood Therapeutics: Addressing A Sickle That Impedes Critical Cycling

2017-10-25 seekingalpha
A company leading the race for a new therapy with a drug in Phase III trials. (35-0)

Your Daily Pharma Scoop: Soliris New Indication, Gilead's NASH Data, What Keeps Synergy Down?

2017-10-25 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service. (546-3)

Gilead Drug Approval Fuels Interest in CAR-T Space: 3 Stocks to Consider

2017-10-23 zacks
Interest in the CAR-T (chimeric antigen receptor T cells) space continues to build up with the FDA giving its nod to the second CAR-T therapy last week. Gilead Sciences’s (GILD - Free Report) Yescarta, a cell-based gene therapy, gained approval for the treatment of adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment. (165-1)

PowerShares Launches Small-Cap Equity ETF

2017-10-18 zacks
The fund seeks to provide exposure to small-cap U.S. equities. It has AUM of $2.6 million and seeks to provide cheap exposure to small-cap equity markets. It charges 6 basis points as fee per year and holds 1804 stocks in its portfolio. It bears less concentration risk as less than 3% of the assets are allocated to the top 10 holdings and is well diversified across sectors. (101-0)

CUSIP: 009609G10